Studies: Gilead drugs protect heterosexuals against HIV

07/13/2011 | New York Times (tiered subscription model), The

Two African studies demonstrated the potential of HIV treatments by Gilead Sciences to protect heterosexuals from infection. The first study, involving "discordant couples," found that uninfected partners taking a daily dose of Truvada were 73% less likely to contract HIV, while those using Viread were 62% less likely to become infected. In the second study, led by the CDC, Truvada reduced the risk of infection by 63% among young adults who were sexually active.

View Full Article in:

New York Times (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Eastern Zone Sales Director
Regenesis Biomedical
Multiple Locations, SL_Multiple Locations
Director, Compliance - Health Plan Privacy & Security
Kaiser Permanente
Oakland, CA
Regulatory Counsel
Food and Drug Administration
Silver Spring, MD
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Vice President, Commercial Markets
Meridian Health
Neptune, NJ